new research link , page-2

1st part bazyou1 reads good this cr i believe will come with positive news all good imo
Summary - Cellmid started year 2013 on a positive note with major updates on their hair loss
and therapeutic programs. We are not surprised to see strong share price action as company
performed extremely well: a) posting first sales for the hair loss product that exceeded our
expectations, b) providing major update on the first therapeutic indication showing strong
preclinical data, c) obtaining a new option to license agreement for its proprietary anti-midkine
diagnostic antibodies for validation on Fujikura's latex platform, providing a strong validation
of midkine’s future potential in the diagnostic space.
We update our Price Target to A$0.072 primarily based on the fact that the company is now
only a few months away from receiving a milestone payment and initial royalty revenues from
the commercial launch of Lung Dx (by Quest Diagnostics) and Cxbladder (by Pacific Edge
Biodiagnostics). We also update our view on commercial opportunity of evolis®
hair loss
product as first sales numbers exceeded our original estimates.